Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Simon

Showing results (91-100 of 124) with videos related to

Pageof 13
Sort By:
Pediatric Blood & Cancer|May 6, 2015
Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastomaEsther M van Wezel, Janine Stutterheim, Florentien Vree, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 25, 2024
Sensitive liquid biopsy monitoring correlates with outcome in the prospective international GPOH-DCOG high-risk neuroblastoma RT-qPCR validation studyLieke M J van Zogchel, Boris Decarolis, Esther M van Wezel, et al.
Frontiers in Pediatrics|October 27, 2022
Presenting features of neuroblastoma with spinal canal invasion. A prospective study of the International Society of Pediatric Oncology Europe - Neuroblastoma (SIOPEN)Stefania Sorrentino, Shifra Ash, Riccardo Haupt, et al.
JCO Precision Oncology|February 1, 2022
Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in NeuroblastomaAndrea Roderwieser, Frederik Sand, Esther Walter, et al.
Cancers|January 11, 2025
Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort StudyTim Flaadt, Jonas Rehm, Thorsten Simon, et al.
JCO Precision Oncology|December 18, 2025
Minimal Residual Disease Detection in Peripheral Blood of Patients With High-Risk Neuroblastoma Correlates With Outcome in the International GPOH-DCOG Prospective Validation StudyNina U Gelineau, Lieke M J van Zogchel, Boris De Carolis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter StudyRochelle Bagatell, Kieran McHugh, Arlene Naranjo, et al.
Klinische Padiatrie|June 5, 2025
Correction: GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025Thorsten Simon, Theresa Thole, Sveva Castelli, et al.
Klinische Padiatrie|May 9, 2025
GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025Thorsten Simon, Theresa Thole, Sveva Castelli, et al.
Bone Marrow Transplantation|May 29, 2026
A pilot study combining primary busulfan-based haploidentical stem cell transplantation with GD2 antibody to treat high-risk neuroblastomaSveva Castelli, Tim Flaadt, Franziska Schulze, et al.
Pageof 13

Showing results (91-100 of 124) with videos related to

Sort By:
Pageof 13
Pediatric Blood & Cancer|May 6, 2015
Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastomaEsther M van Wezel, Janine Stutterheim, Florentien Vree, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 25, 2024
Sensitive liquid biopsy monitoring correlates with outcome in the prospective international GPOH-DCOG high-risk neuroblastoma RT-qPCR validation studyLieke M J van Zogchel, Boris Decarolis, Esther M van Wezel, et al.
Frontiers in Pediatrics|October 27, 2022
Presenting features of neuroblastoma with spinal canal invasion. A prospective study of the International Society of Pediatric Oncology Europe - Neuroblastoma (SIOPEN)Stefania Sorrentino, Shifra Ash, Riccardo Haupt, et al.
JCO Precision Oncology|February 1, 2022
Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in NeuroblastomaAndrea Roderwieser, Frederik Sand, Esther Walter, et al.
Cancers|January 11, 2025
Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort StudyTim Flaadt, Jonas Rehm, Thorsten Simon, et al.
JCO Precision Oncology|December 18, 2025
Minimal Residual Disease Detection in Peripheral Blood of Patients With High-Risk Neuroblastoma Correlates With Outcome in the International GPOH-DCOG Prospective Validation StudyNina U Gelineau, Lieke M J van Zogchel, Boris De Carolis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter StudyRochelle Bagatell, Kieran McHugh, Arlene Naranjo, et al.
Klinische Padiatrie|June 5, 2025
Correction: GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025Thorsten Simon, Theresa Thole, Sveva Castelli, et al.
Klinische Padiatrie|May 9, 2025
GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025Thorsten Simon, Theresa Thole, Sveva Castelli, et al.
Bone Marrow Transplantation|May 29, 2026
A pilot study combining primary busulfan-based haploidentical stem cell transplantation with GD2 antibody to treat high-risk neuroblastomaSveva Castelli, Tim Flaadt, Franziska Schulze, et al.
Pageof 13